v3.26.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Series A Junior [Member]
Preferred Stock [Member]
Preferred Stock Undesignated [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock, Common [Member]
AOCI Attributable to Parent [Member]
Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Mar. 31, 2024 $ 1,110 $ 45,696,761 $ (43,883,527) $ (30,328) $ (2,848) $ 1,781,168 $ 1,781,168
Balance, shares at Mar. 31, 2024 1,110,226              
Common Stock issued in Orocidin business combination $ 3,800 18,996,200 19,000,000 19,000,000
Common Stock issued in Orocidin business combination, shares 3,800,000                  
Exercise of warrants $ 93 895,100 895,193 895,193
Exercise of warrants, shares 92,776                  
Cancellation of liability-classified warrants – Related party 167,000 167,000 167,000
Restricted common Stock issued for services $ 30 138,949 138,979 138,979
Common Stock issued for services, shares 30,000                  
Forgiveness of debt - related party 13,886 13,886 13,886
Vesting of restricted stock units - ESG Advisory Group $ 20 (20)
Vesting of restricted stock units - ESG Advisory Group, shares 19,500                  
Recognition of non-controlling interest in acquisition of Orocidin 450,000 450,000
Orocidin issuance of common stock in capital raise 183,663 183,663 9,667 193,330
Stock-based compensation 527,625 527,625 527,625
Common Stock issued in Bio-Convert business combination, net (See Note 10) $ 12,000 38,985,120 38,997,120 38,997,120
Common Stock issued in Bio-Convert business combination, net, shares 12,000,000                  
Common Stock issued to acquire remaining equity of Orocidin (See Note 10) $ 200 443,508 443,708 (443,708)
Common Stock issued to acquire remaining equity of Orocidin, shares 200,000                  
Net loss (2,901,321) (2,901,321) (15,959) (2,917,280)
Foreign currency translation adjustment 618,233 618,233 618,233
Balance at Mar. 31, 2025 $ 17,253 106,047,792 (46,784,848) (30,328) 615,385 59,865,254 59,865,254
Balance, shares at Mar. 31, 2025 17,252,502              
Restricted common Stock issued for services $ 84 304,716 304,800 304,800
Common Stock issued for services, shares 84,000                  
Stock-based compensation 137,544 137,544 137,544
Net loss (4,001,686) (4,001,686) (45,118) (4,046,804)
Foreign currency translation adjustment 3,699,514 3,699,514 559 3,700,073
Issuance of restricted common stock $ 1,850 4,351,992 4,353,842 4,353,842
Issuance of restricted common stock, shares 1,850,036                  
Equity issued by subsidiary in connection with acquisition of intellectual property 786 786 782 1,568
Repurchase of shares (78,394) (78,394) (78,394)
Repurchase of shares, shares (57,642)                  
Balance at Mar. 31, 2026 $ 19,187 $ 110,842,830 $ (50,786,534) $ (108,722) $ 4,314,899 $ 64,281,660 $ (43,777) $ 64,237,883
Balance, shares at Mar. 31, 2026 19,128,896